We report a 38-year-old patient affected by refractory adult onset Still's disease who achieved a prolonged remission following CD34-selected ABMT. The conditioning regimen was based on the use of CY and antithymocyte globulin. A 3.0 and 2.0 log reduction of T (CD3 + ) and B (CD19 + ) lymphocytes, respectively, was obtained using a Ceprate device to select CD34 + cells from PBSC. In the pre-transplant period (1994-1998) the patient had a chronic persistent disease course with frequent and recurrent systemic articular flares and loss of some functional abilities, despite daily prednisone, pulses of CY and immunosuppressive therapy (CYA or MTX). At the time of ABMT the patient had become non-ambulatory. Within 3 weeks of ABMT the patient showed a marked decrease in joint swelling, and morning stiffness. Joint pain and systemic symptoms disappeared, the patient was able to walk and run and gained general well being. ESR, C-reactive protein and WBC count were significantly decreased, while Hb level increased. This partial remission persisted for at least 1 year after ABMT, although at 15 months of followup a reappearance of moderate synovitis in the knees and wrists was noted. Our data further showed that both patient BM microenvironment and stem-progenitor cell function (as assessed by LTC-IC assay) were damaged even 1 year after CD34-selected ABMT, suggesting that the persistence of these alterations could have facilitated the favorable outcome of the disease following ABMT. Bone Marrow Transplantation (2000) 25, 1307-1310. Keywords: Still's disease; ABMT; CD34 selection; BM microenvironment; stem cells Although BMT for the treatment of autoimmune diseases (AD) was proposed several decades ago, based on animal models and a few human cases reports, it was not until recently that both ABMT and allogeneic BMT were considered as treatment options to potentially cure patients with AD.
recently that both ABMT and allogeneic BMT were considered as treatment options to potentially cure patients with AD. [1] [2] [3] [4] [5] Although the risks of allogeneic BMT remain too high to envisage its routine use for AD, advances in the use of cytokine-mobilized PBSC have led to a significant reduction in mortality from the procedure. Furthermore, a number of recent papers have shown that ABMT is a therapeutic modality that may offer some patients with refractory and severe AD associated with decreased life span, a chance of cure. [4] [5] In a recent report, Wulffraat et al 6 showed that ABMT can induce a long-lasting remission of refractory juvenile chronic arthritis patients. We report a 38-year-old patient affected by refractory adult onset Still's disease (AOSD) who achieved a prolonged partial remission state of the disease following CD34-selected ABMT. To our knowledge, this is the second case in the literature of a patient suffering from refractory AOSD who was successfully treated with BMT.
Case report
In December 1994, a 33-year-old Caucasian man, who was previously healthy, was admitted to the Rheumatology Unit with a 2-month history of spiking fevers of 40°C, evanescent maculopapular rash on the trunk and legs, sore throat, pleuritis, pericarditis, moderate hepato-splenomegaly, polyarthralgias and arthritis of knees, elbows, wrists, proximal interphalangeas and metacarpophalangeal joints. ESR and C-reactive-protein were found to be elevated (124 mm/h and 12.2 mg/dl, respectively). Other laboratory data were: normocytic anemia (Hb 9.8 g/dl), mild neutrophilic leukocytosis (13.0 ϫ 10 9 /l); rheumatoid factor, antinuclear antibodies were negative on repeated controls. A complete laboratory and instrumental examination permitted exclusion of malignancy, infection and vasculitic diseases. The diagnosis of adult onset Still disease (AOSD) was based on the clinical and serologic findings and satisfied all of the Yamaguchi criteria for the preliminary classification of AOSD, established in 1992, that require the presence of major criteria (fever, arthralgias, rash, leukocytosis), minor criteria (sore throat, lymphadenopathy, hepatic enzyme levels elevated, rheumatoid factor and antinuclear antibodies negative), and exclusion criteria Bone Marrow Transplantation (infections, neoplastic disease, other rheumatic disease). For the diagnosis at least five criteria are needed, two of which must be major. 7 High-dose glucocorticoid therapy was started with partial improvement of systemic illness. During the follow-up (1994-1998) the patient had a chronic persistent disease course with frequent and recurrent systemic articular flares, despite daily doses of prednisone ranging from 12.5 to 50 mg and immunosuppressive therapy with CYA, MTX (withdrawn after a few weeks, due to intolerance), reaching only a transient and partial response when i.v. pulses of CY were given at a dose of 1320 mg every 3-4 weeks × 12. He continued to suffer from malaise, persistent and diffuse articular pain, joint swelling, severe morning stiffness, and loss of some functional abilities due to the persistent synovitis in several joints.
In January 1998, he complained of difficulty in walking and became nonambulatory. In October 1998, due to the deterioration of the clinical status, after written consent, he received ABMT. Peripheral blood stem cells (PBSC) were mobilized with rhG-CSF (lenogastrim, 5 g/kg subcutaneous administration daily for 8 days) and CY (4 g/m 2 , 6800 mg in total). PBSC collection was performed in May 1998. + cells, and CFU-GM (colony-forming units granulocyte-macrophage) infused was 2.1 ϫ 10 6 /kg, 7.9 ϫ 10 6 /kg (9.48 ϫ 10 9 in total), and 53.3 ϫ 10 4 /kg, respectively; CD34 + cell purity in the graft was 67%. The conditioning regimen was based on the use of CY (50 mg/kg/day for 4 days; total dose: 13 400 mg) and antithymocyte globulin (ATG, 15 mg/kg for 3 days); however, ATG infusion was stopped at day 1, because of the occurrence of anaphylactic reaction.
Short-term engraftment (neutrophil count Ͼ0.5 ϫ 10 9 /l, platelet count Ͼ20 ϫ 10 9 /l) occurred 8 days after ABMT; 1 year after ABMT the blood cell numbers were within the normal values, except the Hb level, which was found to be slightly reduced. The immunological reconstitution following CD34
+ selected ABMT was rather rapid for both T and NK cells; at day 60 the CD4 count was 0.23 ϫ 10 9 /l. No abnormalities in the main T cell subpopulations (CD3
+ ) was seen after ABMT. However, B cell reconstitution was delayed, and the CD19 count was significantly inferior to pre-transplant values even 1 year after ABMT (Table 1) .
Within 3 weeks of ABMT the patient showed a marked decrease in joint swelling, and morning stiffness; joint pain and systemic symptoms disappeared. ESR, C-reactive protein and WBC count were decreased (65 mm/h 4.1 mg/dl, and 7.8 ϫ 10 9 /l, respectively), while Hb level increased (11.9 g/dl). The partial remission state persisted at 12 months of follow-up; at that time the patient only required low doses of steroids (5-10 mg daily). Over an 18-month follow-up period, the patient was capable of walking, running, cycling and swimming without difficulty and gained general well being, although mild synovitis was still detectable in the knees, wrists, metacarpophalangeal and proximal interphalangeal joints. No infectious diseases were noticed in this patient after ABMT. At 15 months of followup the progressive increase of synovitis required an adjustment of daily dose of steroids up to 12.5-15 mg/day; at this time MTX 10 mg/week was restarted. However, joint swelling and systemic symptoms did not improve, despite these drugs being given for a further 3 months.
Cell culture studies
In this patient, we also evaluated at the onset of his disease the capacity of different stromal cell layers (autologous stroma, AS; and normal bone marrow (BM) stroma, NBMS) to sustain the proliferation of selected CD34 + progenitors in a long-term culture initiating cell (LTC-IC) assay.
8 CD34 + cells were purified through the use of the Ceprate device. The comparative analysis showed that the highest numbers of CFU-GM, generated within the stromal layer after 6 weeks of culture of CD34 Furthermore, long-term culture (LTC) of BM cells have been used as an in vitro model of hematopoiesis to study the interactions between early progenitors, stroma, and regulating factors. To assess the proliferation capabilities of BM samples before and after ABMT, we evaluated the capacity of stromal cells to form confluent monolayers at different time intervals (ranging from 1 to 8 weeks), and we scored the number of colony-forming unit fibroblast (CFU-F), as previously reported. 9 A decreased number of CFU-F and of stromal layer confluence in a LTC assay was noticed after ABMT (CFU-F: 1/3 ϫ 10 6 BM light density (Ͻ1.077 g/ml) cells; LTC at day 21: partial (70%) adherent cell layer), as compared with pre-transplant values (CFU-F: 15/3 ϫ 10 6 BM light density cells; LTC at day 21: confluent cell layer) ( Table 1) .
Short-term colony assays have shown a slight decrease in the number of both CFU-GM and BFU-E after CD34- (Table 1) .
Discussion
Autoimmune diseases are characterized by a breakdown of self-tolerance, resulting in humoral and cell-mediated immune responses directed against self-antigens. These immune responses involve inflammatory processes which may cause tissue destruction. The basic mechanisms underlying AD are still poorly understood; however, according to current views, it has been postulated that CD4 + T cells play a central role in the pathogenesis of several AD regardless of whether these immune responses involve self-specific antibodies, or self reactive T lymphocytes. Although cytokines and chemokines play a key role in the development and maintenance of self-tolerance, the in vivo use of recombinant cytokines such as G-CSF to mobilize PBSC in AD patients proved to be safe without unexpected sideeffects or reported major disease exacerbations. Only occasionally, worsening of disease status and joint swelling was reported in AD patients undergoing mobilization treatment.
In this study, we report the second case in the literature of a patient suffering from refractory AOSD who was successfully treated with CD34-selected ABMT. The first case has been reported by McColl et al, 9 but he was treated with syngeneic progenitor cell transplantation. Considering the possibility that AOSD may evolve in a severe disabling Bone Marrow Transplantation disease in selected cases, or more rarely, in immunoblastic malignant lymphoma, 10 a more aggressive immunosuppressive approach such as ABMT may be taken into account when conventional therapy fails. In this Still's disease patient, the chronic persistent disease course causing severe functional disabilities, and the poor responsiveness to conventional immunosuppressive therapy forced us to perform ABMT. Although the pathogenesis of Still's disease is largely unknown, based on current knowledge it can be postulated that this patient may benefit from ABMT that suppresses the auto-reactive T (and B) cell immunity, and could provide normal immune competence by infusing naive T and B cell precursors. Within a few weeks of ABMT the patient presented showed a marked improvement in clinical status, and gained general well-being. The remission state persisted at 18 months of follow-up, and the patient was capable of walking, running, cycling and swimming, only requiring low doses of steroids. ABMT was well tolerated and no BMT-related complications were observed. However, it should be said that at 15 months of follow-up after ABMT, a mild deterioration of the clinical status was noted, requiring a therapeutic adjustment. However, despite an increased daily dose of prednisone and the administration of MTX the systemic and articular disease remained active.
Long-term culture assay performed in this patient has shown a significantly decreased number of CFU-F and a reduced stromal layer confluence after ABMT, as compared with pre-transplant values, raising the possibility that BM stroma were damaged after ABMT for this Still's disease patient. Furthermore, stroma-based long-term culture assays performed before and after ABMT have shown a significant reduction in the incidence of LTC-IC even 1 year after ABMT. The fact that this reduction was more prominent in AS-derived cell cultures than in NBMS cultures, further supported the concept that both patient BM microenvironment and hemopoietic cell compartment were profoundly altered after ABMT. Although animal models suggest the involvement of both CD34
+ progenitor cells and stromal compartment in autoimmune diseases, 2, 3 it is still an open question whether this phenomenon could be found in humans. Based on our findings it can be speculated that the persistence of an impairment in both patient marrow microenviroment and stem progenitor cells even 1 year after CD34-selected ABMT could have facilitated the favorable outcome of the disease following ABMT.
Curiously, the partial recovery of the marrow microenviroment observed 15 months after ABMT was associated with the transition from a partial remission towards an active disease.
In conclusion, in this paper we report a young patient affected by refractory and severe adult onset Still's disease who achieved a prolonged partial remission state of the disease following CD34-selected ABMT.
